Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Associate Partners:

  • Kotak Mutual Fund
  • Pharmeasy
  • Indiabulls
  • SBI

Presenting Partner

Life Insurance Corporation of India

Moneycontrol

Budget 2022

Technology Partner

Dell Technologies

Associate Partners

Kotak Mutual Fund
Pharmeasy
Indiabulls
SBI
you are here: HomeNewsBiocon
results
Jump to
70 Results Found
  • Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct Jul 12, 2021 07:35 PM IST

    Biocon Q1 PAT seen up 21% YoY to Rs 180.7 cr: ICICI Direct

    Net Sales are expected to increase by 13.4 percent Y-o-Y (up 3.1 percent Q-o-Q) to Rs 1,895.3 crore, according to ICICI Direct.

  • Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan Apr 12, 2021 08:40 PM IST

    Biocon Q4 PAT seen up 54.1% YoY to Rs. 203.4 cr: Sharekhan

    Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.

  • Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct Jan 18, 2021 07:58 PM IST

    Biocon Q3 PAT may dip 1.5% YoY to Rs. 199.7 cr: ICICI Direct

    Net Sales are expected to increase by 15.4 percent Y-o-Y (up 15.7 percent Q-o-Q) to Rs. 2,018.1 crore, according to ICICI Direct.

  • Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak Apr 17, 2019 03:12 PM IST

    Biocon Q4 PAT seen up 35.2% YoY to Rs. 176.2 cr: Kotak

    Net Sales are expected to increase by 31.6 percent Y-o-Y (down 0.1 percent Q-o-Q) to Rs. 1,538.7 crore, according to Kotak.

  • Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan Jan 18, 2019 02:58 PM IST

    Biocon Q3 PAT seen up 106.5% YoY to Rs. 190 cr: Sharekhan

    Net Sales are expected to increase by 32.4 percent Y-o-Y (up 6 percent Q-o-Q) to Rs. 1,400.7 crore, according to Sharekhan.

  • Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct Jan 11, 2019 05:26 PM IST

    Biocon Q3 PAT seen up 105.4% YoY to Rs. 188.7 cr: ICICI Direct

    Net Sales are expected to increase by 30.7 percent Y-o-Y (up 4.6 percent Q-o-Q) to Rs. 1,382.4 crore, according to ICICI Direct.

  • Biocon confident of meeting $200-million revenue guidance target for biologics segment Oct 27, 2018 08:00 AM IST

    Biocon confident of meeting $200-million revenue guidance target for biologics segment

    “We expect momentum in the Biologics segment to continue with new market launches expected later in the year and increase penetrations in markets where our products have already been commercialized,” said Kiran Mazumdar-Shaw, Chairperson and Managing Director of Biocon to analysts.

  • Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan Oct 16, 2018 07:22 PM IST

    Biocon Q2 PAT seen up 38.2% YoY to Rs. 123 cr: Sharekhan

    Net Sales are expected to increase by 19.1 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs. 1,154 crore, according to Sharekhan.

  • Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct Oct 12, 2018 04:07 PM IST

    Biocon Q2 PAT seen up 105.9% YoY to Rs. 141.6 cr: ICICI Direct

    Net Sales are expected to increase by 28.6 percent Y-o-Y (up 10.8 percent Q-o-Q) to Rs. 1,245.4 crore, according to ICICI Direct.

  • Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak Jul 18, 2018 02:08 PM IST

    Biocon Q1 PAT seen up 70.8% YoY to Rs. 138.9 cr: Kotak

    Net Sales are expected to increase by 24.4 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs. 1,162 crore, according to Kotak.

  • Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon Jan 25, 2018 12:57 PM IST

    Biologics biz a large value unlocking opportunity; see revival from Q4: Biocon

    We are going to expand our biosimilars pipeline both with Mylan and Sandoz and beyond on our own, said Kiran Mazumdar Shaw, CMD, Biocon.

  • Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl Jan 24, 2018 02:19 PM IST

    Focus on growth, investments; capacity in Biologics a growth driver: Syngene Intl

    EBITDA Margins around 31-33% with focus on growth and investments are good, said Jonathan Hunt, CEO of Syngene International.

  • Optimistic about entry into generics market; hoping for better returns in H2: Biocon Oct 27, 2017 12:53 PM IST

    Optimistic about entry into generics market; hoping for better returns in H2: Biocon

    In an interview to CNBC-TV18, Kiran Mazumdar Shaw, Chairperson & MD of Biocon spoke about the results and her outlook for the company.

  • Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak Oct 13, 2017 05:40 PM IST

    Biocon Q2 PAT may dip 27.2% YoY to Rs. 107.1 cr: Kotak

    Net Sales are expected to increase by 8.4 percent Y-o-Y (up 9.1 percent Q-o-Q) to Rs. 1018.9 crore, according to Kotak.

  • Have buy rating on Glenmark Pharma: HDFC Securities Jul 28, 2017 11:37 AM IST

    Have buy rating on Glenmark Pharma: HDFC Securities

    In an interview to CNBC-TV18, Amey Chalke of HDFC Securities spoke about Q1 FY18 earnings from pharma sector.

  • Biocon Q1 profit seen down 32% on weak operational performance Jul 27, 2017 11:24 AM IST

    Biocon Q1 profit seen down 32% on weak operational performance

    Operating profit during the quarter may drop 20% to Rs 211.3 crore and margin may contract by 560 basis points to 21.2 percent year-on-year.

  • EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A Apr 28, 2017 07:56 PM IST

    EXCLUSIVE: Biocon open to ‘unlocking value’ in units after 5 years; may look at M&A

    Biocon chairperson Kiran Mazumdar-Shaw told Moneycontrol that the company is focusing on ramping up its biologics business, which accounts for 15 percent of overall revenues, but has the potential to be a game changer.

  • Biocon Q4 adjusted profit may grow 32% on strong operational performance Apr 26, 2017 06:37 PM IST

    Biocon Q4 adjusted profit may grow 32% on strong operational performance

    Operating profit is expected to jump 20 percent year-on-year to Rs 254.4 crore and margin may expand 240 basis points to 23.5 percent in the quarter ended March 2017.

  • Biocon well-poised to be a frontrunner in biosimilars: MD Jan 25, 2017 11:02 AM IST

    Biocon well-poised to be a frontrunner in biosimilars: MD

    Attributing the strong show in Q3FY17 to robust performance in biologics, Biocon Chairperson and MD Kiran Mazumdar-Shaw told CNBC-TV18 that Biocon is well poised to be front-runner in biosimilars. The acceptance of biosimilar Trastuzumab by the USFDA is a huge milestone for Mylan and Biocon, she said.

  • Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA Jan 24, 2017 08:42 AM IST

    Biocon Q3 profit seen up 38% to Rs 142 cr on revenue, EBITDA

    Biopharmaceutical company Biocon's third quarter profit is likely to increase 38 percent year-on-year to Rs 142 crore and revenue may grow 15.5 percent to Rs 965.7 crore.

  • Biosimilars to lead growth; generics to be a small part: Biocon Oct 21, 2016 11:56 AM IST

    Biosimilars to lead growth; generics to be a small part: Biocon

    Biotechnology major Biocon reported 19.8 percent rise in revenue to Rs 796.2 crore year-on-year and margins grew to 25.2 percent from 21.2 percent in the second quarter of FY17. The company‘s standalones sale grew 17 percent in Q2.

  • Biocon Q2 profit seen down 55% at Rs 137cr, revenue may grow 19% Oct 19, 2016 05:12 PM IST

    Biocon Q2 profit seen down 55% at Rs 137cr, revenue may grow 19%

    Biocon's profit is expected to fall 55 percent to Rs 137.2 crore in July-September quarter compared with Rs 305.9 crore in year-ago period, according to average of estimates of analysts polled by CNBC-TV18.

  • Biocon Q2 PAT seen up 2.6% to Rs 171 cr: Centrum Oct 19, 2016 03:08 PM IST

    Biocon Q2 PAT seen up 2.6% to Rs 171 cr: Centrum

    Net Sales are expected to increase by 3.5 percent Q-o-Q (up 21.5 percent Y-o-Y) to Rs 1017 crore, according to Centrum.

  • Will scale up contract mfg; $200 mn capex for key arms: Syngene Jul 22, 2016 01:13 PM IST

    Will scale up contract mfg; $200 mn capex for key arms: Syngene

    Of USD 200 million capex, USD 100 million will go into four key areas- Syngene Research Centre, biologic centre, formulation center, viral testing and the rest in commercial manufacturing, says Jonathan Hunt, CEO of Syngene International.

  • Strong biologics performance boosted Q1: Biocon CMD Kiran Shaw Jul 22, 2016 12:58 PM IST

    Strong biologics performance boosted Q1: Biocon CMD Kiran Shaw

    The most important news that everyone will be tracking is when we submit dossiers in Europe and US for insulin Glargine and that as we have indicated will happen this fiscal, says Kiran Mazumdar Shaw

Sections
ISO 27001 - BSI Assurance Mark